Related Experiment Videos
[Acute biphenotypic leukemia followed by two color flow cytometry]
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology
|October 1, 1989
Summary
This case study highlights acute biphenotypic leukemia treatment. Two-color flow cytometry effectively diagnosed the condition and monitored chemotherapy
Area of Science:
- Hematology
- Immunophenotyping
- Oncology
Background:
- Acute biphenotypic leukemia (ABL) is a rare hematologic malignancy characterized by myeloid and lymphoid lineage features.
- Accurate diagnosis and monitoring of treatment response are critical for managing ABL.
- Traditional diagnostic methods may face challenges in complex leukemia subtypes.
Observation:
- A 33-year-old male presented with fever and fatigue, diagnosed with acute leukemia.
- Immunophenotyping revealed co-expression of B-cell (CD19, CD10) and myeloid (CD13, CD33) markers on blast cells.
- Two-color flow cytometry confirmed simultaneous expression of CD19 and CD33 on the same leukemic cells.
Findings:
- The patient received multi-agent chemotherapy, achieving initial partial remission followed by complete remission.
- Two-color flow cytometry was utilized to monitor the effectiveness of chemotherapy.
- The technique provided valuable insights into treatment response beyond conventional bone marrow examination.
Implications:
- Two-color flow cytometry is a valuable tool for diagnosing acute mixed leukemia (AML).
- This method aids in assessing the efficacy of chemotherapy in acute biphenotypic leukemia.
- Enhanced immunophenotyping can improve patient management and treatment strategies for rare leukemia subtypes.